Bloomberg -- Regeneron Pharmaceuticals Inc. said U.S. regulators halted development of its experimental pain killer after a similar treatment caused the death of bone tissue in another drugmaker’s study. The Food and Drug Administration last week confirmed a case of avascular necrosis involving a drug similar to Regeneron’s anti-nerve growth factor, REGN475/SAR164877, the Tarrytown, New York-based company said in a filing today.
